Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Myelofibrosis

Welcome to The Myelofibrosis Channel

Stay up to date with the latest news on this rare bone marrow malignancy with our expert-led video interviews, as well as podcasts and roundtable discussions. The Myelofibrosis Channel covers different pathways that have been explored to modify myelofibrosis, including novel targeted agents, and much more.

The risk of heart failure in MPNs and the rate of CV-related readmissions following heart failure 1:53
The risk of heart failure in MPNs and the rate of CV-related readmissions following heart failure
Orly Leiva • 9 Dec 2023
An efficacy sub-analysis from the ACE-536-MF-001 study of luspatercept for MF-related anemia 3:19
An efficacy sub-analysis from the ACE-536-MF-001 study of luspatercept for MF-related anemia
Aaron Gerds • 6 Dec 2023
XPORT-MF-044 trial: evaluating selinexor in JAK inhibitor-naïve MF and moderate thrombocytopenia 1:30
XPORT-MF-044 trial: evaluating selinexor in JAK inhibitor-naïve MF and moderate thrombocytopenia
Aaron Gerds • 6 Dec 2023
An update from LIMBER-104: zilurgisertib +/- ruxolitinib in the management of MF-associated anemia 2:21
An update from LIMBER-104: zilurgisertib +/- ruxolitinib in the management of MF-associated anemia
Prithviraj Bose • 11 Dec 2023
The MOST study: differences in disease progression amongst patients with low-risk MF 2:39
The MOST study: differences in disease progression amongst patients with low-risk MF
Aaron Gerds • 6 Dec 2023
JAK inhibition in MF: monotherapy versus combination treatment 2:20
JAK inhibition in MF: monotherapy versus combination treatment
Harinder Gill • 11 Dec 2023
Treating elderly, non-transplant eligible patients with MF 1:56
Treating elderly, non-transplant eligible patients with MF
Aaron Gerds • 6 Dec 2023
Bomedemstat combined with ruxolitinib for the treatment of MF: early results of a Phase II trial 2:41
Bomedemstat combined with ruxolitinib for the treatment of MF: early results of a Phase II trial
Harinder Gill • 11 Dec 2023
TRANSFORM-1: navitoclax + ruxolitinib vs placebo + ruxolitinib in patients with untreated MF 1:58
TRANSFORM-1: navitoclax + ruxolitinib vs placebo + ruxolitinib in patients with untreated MF
Naveen Pemmaraju • 11 Dec 2023
Minimal clinically important difference in patient-reported MF-associated outcomes: MANIFEST arm 3 2:05
Minimal clinically important difference in patient-reported MF-associated outcomes: MANIFEST arm 3
Ruben Mesa • 9 Dec 2023
Identifying predictors for ruxolitinib treatment-related thrombocytopenia in patients with MF 2:08
Identifying predictors for ruxolitinib treatment-related thrombocytopenia in patients with MF
Douglas Tremblay • 9 Dec 2023
Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more 16:35
Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more
Claire Harrison et al. • 11 Dec 2023
Add-on therapy with CK0804 for patients with MF who exhibit a suboptimal response to ruxolitinib 2:08
Add-on therapy with CK0804 for patients with MF who exhibit a suboptimal response to ruxolitinib
Lucia Masarova • 9 Dec 2023
XPORT-MF-034: selinexor plus ruxolitinib in JAK-inhibitor naïve myelofibrosis 0:46
XPORT-MF-034: selinexor plus ruxolitinib in JAK-inhibitor naïve myelofibrosis
Keri Maher • 9 Dec 2023
Momelotinib vs SoC in patients with MF and anemia: an analysis from the SIMPLIFY-2 trial 1:45
Momelotinib vs SoC in patients with MF and anemia: an analysis from the SIMPLIFY-2 trial
Uwe Platzbecker • 29 Nov 2023
Predicting thrombocytopenia as a result of ruxolitinib treatment in MF 1:44
Predicting thrombocytopenia as a result of ruxolitinib treatment in MF
Andrew Kuykendall • 27 Nov 2023

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals